Business Context and Reporting Period
This Form 8-K is a current report filed by FibroGen, Inc. (trading symbol: FGEN) on December 16, 2024. The filing discloses the appointment of a new Chief Financial Officer and details the associated compensatory arrangements. Note: While the request metadata references "KYNTRA BIO, INC.", the filing text explicitly identifies the registrant as FibroGen, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change reported is the appointment of David DeLucia as Chief Financial Officer, effective December 16, 2024. Mr. DeLucia was previously the Vice President of Financial Planning & Analysis and Investor Relations at FibroGen. He brings nearly 15 years of financial leadership experience in the life sciences industry.
Compensatory Arrangements and Risks
The filing details a Change-in-Control Severance Agreement (CIC Severance Agreement) for Mr. DeLucia. Key terms include:
- Termination for Cause: Entitlement limited to earned but unpaid salary and unused paid time off.
- Change-in-Control Termination (CIC Termination):
- 12 months of base salary.
- 0.5 times the current target bonus.
- COBRA premium payments for up to 12 months.
- Full vesting of all outstanding equity awards (stock options, RSUs, and performance RSUs).
- Ordinary Course Termination (without cause):
- 9 months of base salary.
- COBRA premium payments for up to 9 months.
Severance payments are contingent upon the timely execution of a release of claims within 60 days of termination. The filing also notes the execution of a standard indemnification agreement.
Investor Verification Checklist
- Verify the full text of the CIC Severance Agreement referenced as Exhibit 10.4 to the 10-Q filed on May 8, 2023.
- Confirm the specific vesting schedules and current value of Mr. DeLucia's outstanding equity awards to assess potential dilution or expense upon a change in control.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Check for any subsequent filings regarding the departure of the previous CFO, if applicable.